Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation

Eric B. Hoie, Karen K. O’Brien, Katie Neighbors, Shana L. Castillo, Kimberley J. Begley

Research output: Contribution to specialist publicationArticle

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.

Original languageEnglish (US)
Pages32-35
Number of pages4
Volume42
No2
Specialist publicationU.S. Pharmacist
StatePublished - Feb 1 2017

Fingerprint

Anticoagulants
Atrial Fibrillation
Stroke
Drug interactions
Aging of materials
Pharmaceutical Preparations
Drug Interactions
Pharmacists
Cardiac Arrhythmias
Heart Rate
Therapeutics
Population
Dabigatran
apixaban
Rivaroxaban
edoxaban

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Cite this

Hoie, E. B., O’Brien, K. K., Neighbors, K., Castillo, S. L., & Begley, K. J. (2017). Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation. U.S. Pharmacist, 42(2), 32-35.

Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation. / Hoie, Eric B.; O’Brien, Karen K.; Neighbors, Katie; Castillo, Shana L.; Begley, Kimberley J.

In: U.S. Pharmacist, Vol. 42, No. 2, 01.02.2017, p. 32-35.

Research output: Contribution to specialist publicationArticle

Hoie, EB, O’Brien, KK, Neighbors, K, Castillo, SL & Begley, KJ 2017, 'Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation' U.S. Pharmacist, vol. 42, no. 2, pp. 32-35.
Hoie, Eric B. ; O’Brien, Karen K. ; Neighbors, Katie ; Castillo, Shana L. ; Begley, Kimberley J. / Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation. In: U.S. Pharmacist. 2017 ; Vol. 42, No. 2. pp. 32-35.
@misc{443ba2fb4e824043b91a399b204a14b0,
title = "Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation",
abstract = "Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.",
author = "Hoie, {Eric B.} and O’Brien, {Karen K.} and Katie Neighbors and Castillo, {Shana L.} and Begley, {Kimberley J.}",
year = "2017",
month = "2",
day = "1",
language = "English (US)",
volume = "42",
pages = "32--35",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation

AU - Hoie, Eric B.

AU - O’Brien, Karen K.

AU - Neighbors, Katie

AU - Castillo, Shana L.

AU - Begley, Kimberley J.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.

AB - Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.

UR - http://www.scopus.com/inward/record.url?scp=85013946037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013946037&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 32

EP - 35

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -